Edition:
India

Ionis Pharmaceuticals Inc (IONS.OQ)

IONS.OQ on NASDAQ Stock Exchange Global Select Market

54.15USD
17 Nov 2017
Change (% chg)

$-0.21 (-0.39%)
Prev Close
$54.36
Open
$54.23
Day's High
$54.73
Day's Low
$53.87
Volume
147,985
Avg. Vol
447,194
52-wk High
$65.51
52-wk Low
$37.27

Chart for

About

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment,... (more)

Overall

Beta: 2.89
Market Cap(Mil.): $6,907.90
Shares Outstanding(Mil.): 124.35
Dividend: --
Yield (%): --

Financials

BRIEF-Ionis eligible to get nearly $800 mln in milestones from deal with Janssen

* Ionis Pharmaceuticals licenses second orally delivered antisense drug to Janssen

16 Nov 2017

BRIEF-Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen

* Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen for the treatment of FCS

15 Nov 2017

BRIEF-Ionis Pharma, ‍Dynacure announces Dynacure has licensed IONIS-DNM2-2.5(Rx) (Dyn101)​

* Ionis Pharmaceuticals Inc - co, ‍Dynacure announced that Dynacure has licensed IONIS-DNM2-2.5(Rx) (Dyn101)​

09 Nov 2017

BRIEF-Ionis Pharmaceuticals reports Q3 earnings per share $0.00

* Ionis Pharmaceuticals reports financial results and highlights for third quarter 2017

07 Nov 2017

BRIEF-Ionis submits NDA for Inotersen to the U.S. FDA

* Ionis announces submission of new drug application (NDA) for Inotersen to the U.S. fda Source text for Eikon: Further company coverage:

07 Nov 2017

BRIEF-Ionis submits marketing authorization application for Inotersen to the EMA

* Ionis announces submission of marketing authorization application for inotersen to the European Medicines Agency Source text for Eikon: Further company coverage:

03 Nov 2017

BRIEF-Ionis Pharmaceuticals announces plans to open expanded access program to provide Inotersen to patients

* Ionis pharmaceuticals announces plans to open expanded access program to provide Inotersen to patients with hereditary TTR Amyloidosis in the U.S.

27 Oct 2017

BRIEF-IONIS PHARMACEUTICALS TO COLLABORATE WITH SEVENTH SENSE BIOSYSTEMS

* IONIS ENTERS INTO COLLABORATION WITH SEVENTH SENSE BIOSYSTEMS TO SUPPORT DEVELOPMENT OF IMPROVED BLOOD COLLECTION AND DIAGNOSTIC DEVICE

18 Oct 2017

BRIEF-IONIS PHARMACEUTICALS INITIATES IONIS-MAPT RX STUDY IN PATIENTS WITH ALZHEIMER'S DISEASE

* IONIS PHARMACEUTICALS INITIATES CLINICAL STUDY OF IONIS-MAPT RX IN PATIENTS WITH ALZHEIMER'S DISEASE

13 Oct 2017

BRIEF-Akcea and Ionis announce filing of new drug submission for Volanesorsen to Health Canada

* Akcea and Ionis announce filing of new drug submission for volanesorsen to Health Canada

13 Sep 2017

Competitors

Earnings vs. Estimates